Publications by authors named "Chong-Xian Pan"

86Publications

Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer.

Adv Ther (Weinh) 2020 Oct 30;3(10). Epub 2020 Jun 30.

Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento CA 95817.

View Article and Find Full Text PDF
October 2020

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.

Cancer Immunol Immunother 2020 Nov 6;69(11):2305-2317. Epub 2020 Jun 6.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.

View Article and Find Full Text PDF
November 2020

A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models.

Cancers (Basel) 2020 May 21;12(5). Epub 2020 May 21.

Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical School, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
May 2020

Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.

Mol Cancer Ther 2020 04 6;19(4):1070-1079. Epub 2020 Feb 6.

Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.

View Article and Find Full Text PDF
April 2020

A polymer-free, biomimicry drug self-delivery system fabricated via a synergistic combination of bottom-up and top-down approaches.

J Mater Chem B 2018 12 12;6(47):7842-7853. Epub 2018 Nov 12.

Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
December 2018

Fidelity of a PDX-CR model for bladder cancer.

Biochem Biophys Res Commun 2019 09 11;517(1):49-56. Epub 2019 Jul 11.

Center for Cell Reprograming, Department of Pathology, Georgetown University Medical Center, Washington DC, USA; Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA. Electronic address:

View Article and Find Full Text PDF
September 2019

Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.

Nanomedicine 2019 08 2;20:102004. Epub 2019 May 2.

Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA; VA Northern California Health Care System, Mather, CA.. Electronic address:

View Article and Find Full Text PDF
August 2019

Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.

Chem Res Toxicol 2018 12 19;31(12):1293-1304. Epub 2018 Nov 19.

Department of Internal Medicine, Division of Hematology and Oncology , University of California Davis , Sacramento , California 95817 , United States.

View Article and Find Full Text PDF
December 2018

Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.

Clin Genitourin Cancer 2018 12 12;16(6):421-428.e1. Epub 2018 Jul 12.

Division of Hematology Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA.

View Article and Find Full Text PDF
December 2018

Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.

Chem Res Toxicol 2018 10 10;31(10):1042-1051. Epub 2018 Sep 10.

Department of Internal Medicine, Division of Hematology and Oncology , University of California Davis School of Medicine , Sacramento , California 95817 , United States.

View Article and Find Full Text PDF
October 2018

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.

Nanomedicine 2018 04 6;14(3):789-799. Epub 2018 Jan 6.

Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA. Electronic address:

View Article and Find Full Text PDF
April 2018

Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.

Methods Mol Biol 2018 ;1655:319-334

VA Northern California Health Care System, University of California at Davis, Sacramento, CA, USA.

View Article and Find Full Text PDF
May 2018

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Clin Cancer Res 2017 Nov 14;23(21):6580-6591. Epub 2017 Aug 14.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.

View Article and Find Full Text PDF
November 2017

A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.

Int J Cancer 2017 08 15;141(3):604-613. Epub 2017 May 15.

Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA.

View Article and Find Full Text PDF
August 2017

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Mol Cancer Ther 2017 02 30;16(2):376-387. Epub 2016 Nov 30.

Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.

View Article and Find Full Text PDF
February 2017

Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry.

J Urol 2016 11 18;196(5):1378-1382. Epub 2016 May 18.

University of California Davis Comprehensive Cancer Center, Sacramento, California. Electronic address:

View Article and Find Full Text PDF
November 2016

Diagnostic Microdosing Approach to Study Gemcitabine Resistance.

Chem Res Toxicol 2016 11 10;29(11):1843-1848. Epub 2016 Oct 10.

Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.

View Article and Find Full Text PDF
November 2016

Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.

Nanotechnology 2016 Oct 19;27(42):425103. Epub 2016 Sep 19.

Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
October 2016

Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Biomaterials 2016 10 22;104:339-51. Epub 2016 Jul 22.

Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA; VA Northern California Health Care System, Mather, CA 95655, USA; Department of Urology, University of California Davis, Sacramento, CA 95817, USA. Electronic address:

View Article and Find Full Text PDF
October 2016

Lipid Cross-Linking of Nanolipoprotein Particles Substantially Enhances Serum Stability and Cellular Uptake.

ACS Appl Mater Interfaces 2016 Aug 4;8(32):20549-57. Epub 2016 Aug 4.

Department of Internal Medicine, Division of Hematology and Oncology, University of California-Davis (UC Davis) and UC Davis Comprehensive Cancer Center , 4501 X Street, Room 3016, Sacramento, California 95817, United States.

View Article and Find Full Text PDF
August 2016

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Cancer 2016 06 28;122(12):1897-904. Epub 2016 Mar 28.

Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis, Sacramento, California.

View Article and Find Full Text PDF
June 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article and Find Full Text PDF
May 2016

Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity.

Chem Res Toxicol 2015 Dec 11;28(12):2250-2. Epub 2015 Nov 11.

Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis , 4501 X Street, Room 3016, Sacramento, California 95817, United States.

View Article and Find Full Text PDF
December 2015

Nanotechnology in bladder cancer: current state of development and clinical practice.

Nanomedicine (Lond) 2015 ;10(7):1189-201

Department of Internal Medicine, Division of Hematology & Oncology, University of California Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
January 2016

Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Nanomedicine (Lond) 2014 17;9(12):1807-20. Epub 2014 Mar 17.

Division of Hematology & Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis, 4501 X Street, Room 3016, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
June 2015

Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry.

Urology 2013 Oct;82(4):840-5

Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA.

View Article and Find Full Text PDF
October 2013

Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Bioanalysis 2013 Feb;5(3):369-91

Accelerated Medical Diagnostics, Inc., 2121 Second Street, B101, Davis, CA 95618, USA.

View Article and Find Full Text PDF
February 2013

Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer.

Nanomedicine (Lond) 2013 Aug 2;8(8):1239-51. Epub 2012 Dec 2.

Division of Hematology & Oncology, Department of Internal Medicine, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
August 2013

Contemporary management of muscle-invasive bladder cancer.

Expert Rev Anticancer Ther 2012 Jul;12(7):941-50

Department of Urology, University of California Davis, 4860 Y Street, Suite 3500, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
July 2012

Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.

Int J Nanomedicine 2012 6;7:2793-804. Epub 2012 Jun 6.

Division of Hematology and Oncology, Department of Internal Medicine, University of California- Davis, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
January 2013

Progress in personalizing chemotherapy for bladder cancer.

Adv Urol 2012 13;2012:364919. Epub 2012 Feb 13.

Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
August 2012

Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.

Clin Genitourin Cancer 2012 Jun 28;10(2):93-8. Epub 2012 Feb 28.

Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
June 2012

Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.

Nanomedicine 2012 Oct 23;8(7):1116-24. Epub 2011 Dec 23.

Department of Internal Medicine, Division of Hematology/Oncology, University of California at Davis, Sacramento, California, USA.

View Article and Find Full Text PDF
October 2012

Current treatment of metastatic bladder cancer and future directions.

Expert Rev Anticancer Ther 2011 Dec;11(12):1851-62

Division of Hematology and Oncology, Department of Internal Medicine and Department of Urology, University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
December 2011

Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.

Invest New Drugs 2012 Oct 21;30(5):2001-7. Epub 2011 Oct 21.

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
October 2012

The clinical and therapeutic implications of cancer stem cell biology.

Expert Rev Anticancer Ther 2011 Jul;11(7):1131-43

Department of Pathology, Indiana University School of Medicine, 350 West 11th Street, Room 4010, Indianapolis, IN 4620, USA.

View Article and Find Full Text PDF
July 2011

MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.

Int J Cancer 2012 Jun 2;130(11):2526-38. Epub 2011 Dec 2.

Department of Urology, University of California, Davis, School of Medicine and Cancer Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
June 2012

The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.

Future Oncol 2011 Apr;7(4):519-41

Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, Clarian Pathology Laboratory Room 4010, Indianapolis, IN 46202, USA.

View Article and Find Full Text PDF
April 2011

Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand.

Mol Cancer 2011 Jan 27;10(1). Epub 2011 Jan 27.

Division of Hematology and oncology, Department of Internal Medicine, University of California-Davis Cancer Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
January 2011

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Int J Cancer 2011 Sep 4;129(6):1425-34. Epub 2011 Mar 4.

Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
September 2011

Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.

Anticancer Res 2010 Nov;30(11):4573-8

Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
November 2010

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

Chem Res Toxicol 2010 Nov 28;23(11):1653-5. Epub 2010 Oct 28.

Division of Hematology & Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, California 95817, USA.

View Article and Find Full Text PDF
November 2010

Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach.

Urol Oncol 2012 Sep 2;30(5):635-45. Epub 2010 Oct 2.

Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
September 2012

The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer.

Cancer 2010 Jun;116(11):2596-603

Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis, Sacramento, California, USA.

View Article and Find Full Text PDF
June 2010

Rainbow beads: a color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries.

J Comb Chem 2008 Jul-Aug;10(4):599-604. Epub 2008 Jun 18.

Division of Hematology & Oncology, Department of Internal Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, California 95817, USA.

View Article and Find Full Text PDF
September 2008

Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.

Clin Cancer Res 2007 Oct;13(20):6204-16

Department of Urology, University of California, Davis, School of Medicine and Cancer Center, Sacramento, California 95817, USA.

View Article and Find Full Text PDF
October 2007

From combinatorial chemistry to cancer-targeting peptides.

Mol Pharm 2007 Sep-Oct;4(5):631-51. Epub 2007 Sep 20.

U.C. Davis Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, University of California-Davis, 4501 X Street, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
December 2007

Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.

World J Urol 2007 Aug 12;25(4):393-9. Epub 2007 Jun 12.

Department of Urology, University of California, Davis Medical Center, 4860 Y St, Suite 3500, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
August 2007

Small-cell carcinoma of the urinary bladder: diagnosis and management.

Expert Rev Anticancer Ther 2006 Dec;6(12):1707-13

University of California at Davis, Department of Internal Medicine, Division of Hematology/Oncology, Department of Urology, 4501 X Street, Room 3016, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
December 2006

Implications of cancer stem cells in the treatment of cancer.

Future Oncol 2006 Dec;2(6):723-31

University of California at Davis Cancer Center, 4501 X Street, Room 3016, Sacramento, CA 95817, USA.

View Article and Find Full Text PDF
December 2006

Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.

J Urol 2005 Sep;174(3):898-902

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA.

View Article and Find Full Text PDF
September 2005

Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.

Mod Pathol 2005 Aug;18(8):1022-6

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

View Article and Find Full Text PDF
August 2005

Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.

Am J Pathol 2005 May;166(5):1533-9

Department of Pathology and Laboratory Medicine, Indiana University Medical Center, University Hospital 3465, 550 North University Boulevard, Indianapolis, Indiana 46202, USA.

View Article and Find Full Text PDF
May 2005

Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder.

Cancer 2004 Jul;101(1):183-8

Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University Medical Center, University Hospital 3465, 550 North University Boulevard, Indianapolis, IN 46202, USA.

View Article and Find Full Text PDF
July 2004

Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.

Cancer 2004 Jul;101(1):83-9

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, University Hospital 3465, University Medical Center, 550 North University Boulevard, Indianapolis, IN 46202, USA.

View Article and Find Full Text PDF
July 2004

Loss of 14-3-3sigma in prostate cancer and its precursors.

Clin Cancer Res 2004 May;10(9):3064-8

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

View Article and Find Full Text PDF
May 2004